A controlled pilot study showed that atorvastatin treatment in COPD patients significantly reduced the neutrophil count in sputum by 34% and the CD45+ cell count by 57% in lung biopsies (P = 0.008)13. The gene discussed is PTPRC; the disease is chronic obstructive pulmonary disease.